# Pilot Study to Evaluate the Safety and Efficacy of 5-ALA-SFC in Type II Diabetes

> **NCT02481141** · NA · COMPLETED · sponsor: **SBI Pharmaceuticals Co, Ltd.** · enrollment: 53 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** 5-ALA-SFC
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02481141
- **Lead sponsor:** SBI Pharmaceuticals Co, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07
- **Primary completion:** 2015-07
- **Final completion:** 2015-07
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2018-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02481141

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02481141, "Pilot Study to Evaluate the Safety and Efficacy of 5-ALA-SFC in Type II Diabetes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02481141. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*